David Wraith is Professor of Immunology, Director of the Institute of Immunology and Immunotherapy at the University of Birmingham and CSO of Apitope NV, a University of Bristol spinout company that designs and develops peptides for antigen-specific immunotherapy of allergic and autoimmune diseases. David began his career at NIMR, London, working on the immune response to viruses. He received MRC funding to study autoimmunity at Stanford University. This led to him establishing a Wellcome Trust funded research laboratory at the University of Cambridge and, in 1995, he took up the Chair in Experimental Pathology in Bristol. His research group is principally supported by the Wellcome Trust and MRC.